References
  1. Phanuphak N and Gulick RM. HIV treatment and prevention 2019: current standards of care. Curr Opin HIV AIDS 2020 Jan;15(1):4-12.
  2. Gameiro J, Jorge S and Lopes JA. HIV and renal disease: a contemporary review. Int J STD AIDS 2018 Jun;29(7):714-719.
  3. European AIDS Clinical Society (EACS) GuidelinesVersion 9.1: European AIDS Clinical Society (EACS); 2018. http://www.eacsociety.org/ files/2018_guidelines-9.1-english.pdf. Accessed 13 Jan 2019.
  4. Cid‐Silva P, Fernández‐Bargiela N, Margusino‐Framiñán L, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124(4):479–490.
  5. Wyatt CM, Klotman PE. Overview of kidney disease in HIV-positive patients UpToDate,Sep 2020.
  6. Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207: 1359–69.
  7. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667–78.
  8. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867–75.
  9. Alfano G, Cappelli G, Fontana F, et al. Kidney Disease in HIV Infection. J Clin Med. 2019 Aug 19;8(8):1254.
  10. Lundgren JD, Babiker AG, Gordin F, et al. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795 – 807.
  11. Danel C, Moh R, Gabillard D, et al. TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808 – 822.
  12. Milburn J, Jones R and Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant (2017) 32: 434–439.
  13. WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV Interim guidance. World Health Organization; 2019 https://www.who.int/hiv/pub/guidelines/ ARV2018update/en/.
  14. Tan Q, He YH, Yang TT, et al. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients. Journal of Microbiology, Immunology and Infection (2019) 52, 710-719.
  15. Patel KK, Patel AK, Ranjan RR, et al. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from western India. Indian J Sex Transm Dis. 2010;31:30–4.
  16. Izzedine H, Isnard-Bagnis C, Hulot J-S, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18:1074–6.
  17. Pinto Neto LF, Bassetti BR, Fraga IH, et al. Nephrotoxicity during tenofovir treatment: a three-year follow-up study in a Brazilian reference clinic. Braz J Infect Dis. 2016;20(1):14–18.
  18. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of Tenofovir Diproxil Fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505.
  19. Mocroft A, Lundgren JD, Ross M, et al. for the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study*. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV 2016; 3(1): e23–32.
  20. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014; 67: 52–58.
  21. Aloy B, Tazi I, Bagnis CI, et al. Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys? AIDS Rev. Oct-Dec 2016;18(4):184-192.
  22. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 2020; 396: 239–54.
  23. Sax PE, Wohl D, Yin MT, et al. For the GS-US-292-0104/0111 Study Team*. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385: 2606–15.
  24. MS,  CA, ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS. 2019 Feb;30(2):181-187.
  25. Lindeman TA, Duggan JM, Sahloff EG. Evaluation of serum creatinine changes with integrase inhibitor use in human immunodeficiency virus-1 infected adults. Open Forum Infect Dis. 2016;3(2):ofw053.
  26. Koteff J, Borland J, Chen S, et al. A Phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990–6.
  27. Raffi. F, Rachlis A, Stellbrink HJ, et al. On behalf of the SPRING-2 study group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735–43.
  28. Singh RP, Shaik JSB, Skoura N, et al. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults. J Acquir Immune Defic Syndr. 2018 Dec 15; 79(5): 631–638.
  29. Walmsley S, Baumgarten A, Berenguer J, et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9.